针对MYC的PROTACs导致双向降解和N端截断
Shelton R Boyd1, Srinivas Chamakuri2, Alexander J Trostle3,4
1Verna and Marrs McLean Department of Biochemistry and Molecular Pharmacology, Baylor College of Medicine, One Baylor Plaza, Houston, Texas 77030, United States.
ACS chemical biology
|March 27, 2025
概括
针对MYC癌症蛋白的蛋白质溶解向嵌合体 (PROTACs) 显示了潜在的潜力. PROTAC MTP3消耗MYC并产生一个截断的形式,tMYC,维持癌细胞的增殖.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 生物化学 生化学
背景情况:
- MYC是驱动癌症发展的关键转录因子.
- 它的混乱结构阻碍了传统的小分子抑制剂的开发.
- 针对MYC降解是一种有前途的治疗策略.
研究的目的:
- 研究PROTACs在降解MYC.中的有效性.
- 评估MYC被PROTACs降解是否会导致癌细胞死亡的增强.
- 为了描述一种新的MYC向PROTAC,MTP3.3的影响.
主要方法:
- 设计和合成PROTAC MTP3,一种改性MYC向化合物.
- 评估MTP3对内源MYC蛋白水平的影响.
- 分析MTP3.3诱导的MYC截断对功能和监管的影响.
主要成果:
- MTP3成功地消耗了全长的MYC.
- MTP3独特地增加了一个截断的MYC物种 (tMYC) 的水平.
- 虽然tMYC缺乏N端的交换激活域,但它仍然保持着致癌的增殖状态.
结论:
- 在简单的目标降解之外,PROTACs可以诱导复杂的结果.
- 针对MYC的PROTAC在癌症治疗中提出了独特的挑战和可能性.
- 截断的MYC物种,tMYC,在维持癌症进展方面发挥着重要作用.
相关概念视频
The Proteasome
10.6K
Eukaryotic cells can degrade proteins through several pathways. One of the most important amongst these is the ubiquitin-proteasome pathway. It helps the cell eliminate the misfolded, damaged, or unwarranted cytoplasmic proteins in a highly specific manner.
In this pathway, the target proteins are first tagged with small proteins called ubiquitin. A series of enzymes carry out the ubiquitination of the target proteins - E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme), and E3...
In this pathway, the target proteins are first tagged with small proteins called ubiquitin. A series of enzymes carry out the ubiquitination of the target proteins - E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme), and E3...
10.6K
Regulated Protein Degradation
9.3K
It is vital to regulate the activity of enzymatic as well as non-enzymatic proteins inside the cell. This can be achieved either through creating a balance between their rate of synthesis and degradation or regulating the intrinsic activity of the protein. Both these regulation mechanisms play an essential role in the normal functioning of cells.
Protein degradation plays two important roles in the cells. It helps to protect cells from misfolded or damaged proteins before they lead to a...
Protein degradation plays two important roles in the cells. It helps to protect cells from misfolded or damaged proteins before they lead to a...
9.3K
Abnormal Proliferation
5.4K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
5.4K
Targeted Cancer Therapies
9.1K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
9.1K
Regulated Protein Degradation
3.4K
No description available
3.4K
The Proteasome
2.0K
Eukaryotic cells can degrade proteins through several pathways. One of the most important among these is the ubiquitin-proteasome pathway. It helps the cell eliminate the misfolded, damaged, or unwarranted cytoplasmic proteins in a highly specific manner.
In this pathway, the target proteins are first tagged with small proteins called ubiquitin. This involves participation of a series of enzymes including— E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme), and E3...
In this pathway, the target proteins are first tagged with small proteins called ubiquitin. This involves participation of a series of enzymes including— E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme), and E3...
2.0K


